These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 28888219

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA.
    N Engl J Med; 2015 Dec 17; 373(25):2413-24. PubMed ID: 26559317
    [Abstract] [Full Text] [Related]

  • 63. The Influence of Assay Selection on Prothrombin Time Measured in Patients Treated With Rivaroxaban for Nonvalvular Atrial Fibrillation.
    Shimomura D, Nakagawa Y, Kondo H, Tamura T, Amano M, Enomoto S, Onishi N, Tamaki Y, Miyake M, Kaitani K, Izumi C, Fukuda A, Nakamura F, Kawano S.
    J Clin Lab Anal; 2016 Nov 17; 30(6):941-946. PubMed ID: 27075709
    [Abstract] [Full Text] [Related]

  • 64. Measurement of rivaroxaban concentrations demonstrates lack of clinical utility of a PT, dPT and APTT test in estimating levels.
    Thom I, Cameron G, Robertson D, Watson HG.
    Int J Lab Hematol; 2018 Aug 17; 40(4):493-499. PubMed ID: 29718586
    [Abstract] [Full Text] [Related]

  • 65. Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban.
    Tripodi A, Martinelli I, Chantarangkul V, Clerici M, Artoni A, Passamonti S, Peyvandi F.
    Int J Hematol; 2016 Feb 17; 103(2):165-72. PubMed ID: 26586461
    [Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
    Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI.
    JAMA Cardiol; 2017 May 01; 2(5):566-574. PubMed ID: 28355459
    [Abstract] [Full Text] [Related]

  • 69. Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum.
    Siddiqui F, Hoppensteadt D, Jeske W, Iqbal O, Tafur A, Fareed J.
    Clin Appl Thromb Hemost; 2019 May 01; 25():1076029619847524. PubMed ID: 31088146
    [Abstract] [Full Text] [Related]

  • 70. Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban.
    Jourdi G, Siguret V, Martin AC, Golmard JL, Godier A, Samama CM, Gaussem P, Gouin-Thibault I, Le Bonniec B.
    Thromb Haemost; 2015 Jul 01; 114(1):78-86. PubMed ID: 25761505
    [Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study.
    Tsantes AE, Kyriakou E, Ikonomidis I, Katogiannis K, Papadakis I, Douramani P, Kopterides P, Kapsimali V, Lekakis J, Tsangaris I, Bonovas S.
    Medicine (Baltimore); 2016 Apr 01; 95(14):e3037. PubMed ID: 27057830
    [Abstract] [Full Text] [Related]

  • 79. Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.
    Ikeda T, Atarashi H, Inoue H, Uchiyama S, Kitazono T, Yamashita T, Shimizu W, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida A, Ako J, Sugishita N, Shimizu S, Shimokawa H.
    Tohoku J Exp Med; 2016 Dec 01; 240(4):259-268. PubMed ID: 27904005
    [Abstract] [Full Text] [Related]

  • 80. Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery.
    Kröll D, Stirnimann G, Vogt A, Lai DLL, Borbély YM, Altmeier J, Schädelin S, Candinas D, Alberio L, Nett PC.
    Br J Clin Pharmacol; 2017 Jul 01; 83(7):1466-1475. PubMed ID: 28121368
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.